Patients with connective tissue disease-related interstitial lung disease show slower decline in lung function and longer ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood ...

This new article publication from Acta Pharmaceutica Sinica B, discusses how SRSF7 promotes pulmonary fibrosis through regulating PKM alternative splicing in lung fibroblasts.

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, ...

Panelists discuss how emerging, better-tolerated oral therapies for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) could improve patient adherence and simplify treatment ...

GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with ...

GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease ...

Panelists discuss that improving outcomes for patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) requires multifaceted efforts including developing ...

Pulmonary fibrosis is not infectious like TB. No one knows the cause of most types of pulmonary fibrosis, specifically Idiopathic Pulmonary Fibrosis (IPF).